2,287 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Acquired by Impact Capital Partners LLC

Impact Capital Partners LLC bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 2,287 shares of the medical research company's stock, valued at approximately $422,000.

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc raised its stake in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. increased its holdings in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after acquiring an additional 173 shares during the last quarter. Pinnacle Bancorp Inc. increased its holdings in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Tortoise Investment Management LLC increased its holdings in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after acquiring an additional 115 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Charles River Laboratories International in the 3rd quarter worth about $59,000. 98.91% of the stock is currently owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

Several brokerages recently weighed in on CRL. The Goldman Sachs Group decreased their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Barclays decreased their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a report on Tuesday, February 18th. Morgan Stanley decreased their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus price target of $198.36.

Insider Transactions at Charles River Laboratories International

In other news, COO Birgit Girshick bought 1,514 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at $9,064,198.54. This represents a 2.83 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded up $2.01 during midday trading on Tuesday, hitting $177.02. 1,011,923 shares of the company's stock were exchanged, compared to its average volume of 1,191,839. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $274.77. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market cap of $9.05 billion, a price-to-earnings ratio of 1,180.13, a PEG ratio of 4.54 and a beta of 1.45. The business's fifty day moving average price is $167.46 and its two-hundred day moving average price is $184.33.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the firm earned $2.46 earnings per share. Charles River Laboratories International's revenue was down 1.1% on a year-over-year basis. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).